SAN DIEGO --(BUSINESS WIRE)--Mar. 31, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports unaudited net revenue for 2021 of $61.2 million and cash and cash equivalents as of December 31, 2021 of approximately $28 million .
CNSide™ study data featured in three poster presentations at leading neuro-oncology annual meeting Participates in UCSF investigator-initiated study to better understand the development and progression of metastatic breast cancer to the central nervous system CNSide orders increased 8% over 2Q 2022
Revenues for the third quarter of $17.5 million , up 165% over prior-year quarter, driven by increased RT-PCR COVID-19 testing, resulting in profitability; cash balance of $27.7 million at quarter-end Robust CNSide™ sequential-quarter volume growth; continued customer base expansion Data generated
Revenues of $6.6 million - a result of decision to offer COVID-19 testing Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO , Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to
- Revenues reached a record $1.5 million, up 101% over the third quarter of 2018 and up 28% over the second quarter of 2019 - The number of commercial samples received increased 66% over the third quarter of 2018 and 12% over the second quarter of 2019 - Cost of revenue reduced 23% on a per
Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , Nov. 13, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer
-- Despite the impact from natural disasters and fewer sales days, revenues were up 6% and 111% in 3Q 2017 and year to date, respectively, versus the prior-year periods inclusive of the impact of conversion to accrual-based revenue recognition-- Distribution agreement signed with VWR to distribute Biocept's patented blood collection tube-- Co-Marketing agreement signed with Miraca Life Sciences-- Pathology Program initiative underway to expand adoption of Biocept's Target Selector™ platform to more community pathologists, oncologists and hematologists-- Newly launched liquid biopsy tests complete the complement of biomarker testing for breast cancer, metastatic melanoma and colorectal cancer under NCCN® Guidelines and bring the total number of commercially available liquid biopsy tests to 15-- Company to host conference call at 4:30 p.m. Eastern time today
Expands leadership position by launching additional tumor-associated blood-based biomarker assaysDrives 43% sequential growth in commercial assaysConference call begins at 4:30 p.m. Eastern time today
SAN DIEGO, Nov. 13, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced its financial results for the third quarter ended September 30,
SAN DIEGO --(BUSINESS WIRE)--Aug. 14, 2023-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2023 and provides a business update.
